2023-07-20 17:33:15 ET
ADC Therapeutics ( NYSE: ADCT ) stock rose 6% in after-hours trading following news that it was discontinuing a Phase 2 study for its drug Zynlonta in the treatment of lymphoma over safety concerns.
The biotech company temporarily halted the study, called LOTIS-9, earlier this month due to a potentially high number of treatment-emergent adverse events. ADC had been testing Zynlonta in combination with rituximab as a first-line treatment in frail and unfit patients with diffuse large B-cell lymphoma, or DLBCL.
ADC said that the US Food and Drug Administration placed a partial clinical hold on new patient enrollment Wednesday, but is allowing patients who were benefitting from the drug to keep taking it. The company doesn't intend to pursue studying the drug regimen in untreated DLBCL patients who are frail and unfit.
Zynlonta is already approved in the US and EU as a treatment for relapsed or refractory large B-cell lymphoma in adult patients who have already been administered two or more systemic therapies.
More on ADC Therapeutics:
- ADC Therapeutics falls after pausing mid-stage trial for lead asset
- ADC Therapeutics: Maybe A 2024 Story
- ADC Therapeutics SA 2023 Q1 - Results - Earnings Call Presentation
- ADC Therapeutics SA ( ADCT ) Q1 2023 Earnings Call Transcript
For further details see:
ADC Therapeutics discontinues Zynlonta study over safety concerns